Pharma Marketing Network

In June, the FDA issued a THIRD draft guidance document regarding reprint distribution by pharmaceutic companies. This new guidance describes FDA’s recommendations for distributing...

FDA Targets Companies for Facebook 'Likes.' Is Twitter 'Favorites' Next?

Rich Meyer initiated quite a controversy on his World of DTC Marketing blog when he posted a "guest" article by an anonymous "Senior Director...

According to a "Client Alert" from Pillsbury Winthrop Shaw Pittman LLP, FDA’s new draft guidance that would exempt from premarket 510(k) review many low-risk...

Pharmaguy interviews Preeti Pinto, former Executive Director & Head of Promotional Regulatory Affairs at AstraZeneca. We talk about the Advertising and Promotions Course that Preeti will teach at the Temple University School of Pharmacy this fall. Delve into the regulatory intricacies of Rx Drugs advertising!

You don't hear much about it, but pharma advertises on mobile devices. An Astellas marketing campaign for its overactive bladder drug, Myrbetriq, for example,...

A new study by researchers from Cambridge Health Alliance/Harvard Medical School, Boston Medical Center (BMC)/Boston University School of Medicine (BUSM), City University of New...

These days, patient storytelling is all the rage. More often than not, however, patient stories told by pharma marketers are not 'providing truth' in the sense that they are real patient stories.

Sooner or later Congress, perhaps urged on by patient advocates or some mhealth app adverse event, may investigate the mobile health app industry -- including the drug industry -- to see if further oversight, not just FDA regulations, is required. Before that happens and to ensure that mobile health apps developed by pharma are of the highest quality, the industry should differentiate itself from "wild west" developers by being pro-active in developing and abiding by a set of 'Guiding Principles for Mobile Health Apps.'

Welcome to Volume 13, Issue #7 (AUGUST 2014) of Pharma Marketing News.